Anzeige
Mehr »
Donnerstag, 25.06.2026 - Börsentäglich über 12.000 News
Tiefseebergbau erfordert echte Offshore-Expertise
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 897518 | ISIN: US62855J1043 | Ticker-Symbol: MYD
Stuttgart
25.06.26 | 21:55
4,730 Euro
+16,05 % +0,654
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
MYRIAD GENETICS INC Chart 1 Jahr
5-Tage-Chart
MYRIAD GENETICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
4,7684,95022:16
4,6864,83722:00

Aktuelle News zur MYRIAD GENETICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiMyriad Genetics, Inc.: Myriad Genetics Expands Availability of Precise MRD for Colorectal, Renal and Breast Cancers, Supported by New Publication121SALT LAKE CITY, June 23, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces expanded availability of Precise...
► Artikel lesen
DiDaniel Skovronsky verlässt Aufsichtsrat von Myriad Genetics1
DiMYRIAD GENETICS INC - 8-K, Current Report1
04.06.MYRIAD GENETICS INC - 8-K, Current Report3
04.06.MYRIAD GENETICS INC - S-8, Securities to be offered to employees in employee benefit plans3
02.06.Myriad Genetics ernennt Raj Jampa zum neuen Chief Technology Officer2
02.06.Myriad Genetics names Raj Jampa as chief technology officer1
MYRIAD GENETICS Aktie jetzt für 0€ handeln
02.06.Myriad Genetics Appoints Raj Jampa As CTO1
02.06.Myriad Genetics, Inc.: Myriad Genetics Names Raj Jampa as New Chief Technology Officer185SALT LAKE CITY, June 02, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announces today the appointment of Raj Jampa...
► Artikel lesen
28.05.Is MYGN Stock a Buy at 0.4x Sales? What Investors Should Weigh2
28.05.Myriad Genetics' Upcoming Prolaris + AI Test Debut May Lift Its Stock8
27.05.Myriad Genetics, Inc.: Myriad Genetics Highlights Data Showing Broad Clinical Utility of Precise MRD Assay at 2026 ASCO Annual Meeting2
26.05.Myriad Genetics launches Prolaris + AI prostate cancer test4
26.05.Myriad Genetics, Inc.: Myriad Genetics Launches Prolaris + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence (AI)378SALT LAKE CITY, May 26, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announces the launch of the Prolaris + AI Test...
► Artikel lesen
15.05.Myriad Genetics, Inc.: Actress Jackie Tohn Got Results Nobody Wants But They May Have Saved Her Life5
06.05.Myriad Genetics in record sell-off after Q1 miss15
06.05.MYRIAD GENETICS INC - 10-Q, Quarterly Report-
06.05.Myriad Genetics Q1 2026 slides: cancer growth offsets prenatal decline26
06.05.Myriad Genetics Q1 Loss Widens18
05.05.Myriad Genetics Non-GAAP EPS of -$0.09 misses by $0.02, revenue of $200.4M misses by $2.04M7
Weiter >>
60 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1